Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herbal remedy investigation

This article was originally published in The Tan Sheet

Executive Summary

FDA is investigating the toxic potential of Chinese herbal remedy Jin Bu Haun, which is used as a sedative and analgesic, according to the Centers for Disease Control and Prevention's Dec. 3 Morbidity and Mortality Weekly Report. CDC noted that in July and August 1993, three women in Los Angeles developed acute hepatitis after ingesting Jin Bu Huan, which has previously been associated with the onset of acute hepatitis. CDC recommended in the Aug. 27 MMWR that traditional ethnic remedies (including Jin Bu Huan) should-be sold in child-proof packaging due to their toxic potential. CDC also had reported that in 1993 three children in Colorado experienced central nervous system and respiratory depression leading to life-threatening bradycardia after an unintentional overdose of Jin Bu Huan.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel